newsfilter
← Latest News
GlobeNewswire·

argenx Provides Update on UplighTED Studies of Efgartigimod SC in Thyroid Eye Disease

15 December, 2025, 7:00 AM CET Amsterdam, the Netherlands – argenx SE ((Euronext &, NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases,